Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2436
Source ID: NCT02987348
Associated Drug: Exenatide Once Weekly
Title: Clinical Outcomes of Exenatide Versus Basal Insulin
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes
Interventions: DRUG: exenatide once weekly|DRUG: exenatide twice daily|DRUG: basal insulin
Outcome Measures: Primary: Changes from baseline in HbA1c (%), Changes in HbA1c at 6 months, 12 months and 24 months after initiation of the treatment with exenatide and basal insulin will be calculated and compared., 6, 12 and 24 months|Changes from baseline in weight (kg), Changes in weight at 6 months, 12 months and 24 months after initiation of the treatment with exenatide and basal insulin will be calculated and compared., 6, 12 and 24 months|Changes from baseline in composite outcomes of HbA1c<=7.0% and weight reduction, Changes in composite outcome of HbA1c\<=7.0% and any weight reduction or HbA1c\<=7.0% and weight reduction\>=5% at 6 months, 12 months and 24 months after initiation of the treatment with exenatide and basal insulin will be calculated and compared., 6, 12 and 24 months | Secondary: Health care utilization, Costs of health service contacts after initiation of therapy with exenatide and basal insulin will be calculated and compared using the Mann-Whitney U-test., 12 months
Sponsor/Collaborators: Sponsor: AstraZeneca
Gender: ALL
Age: CHILD, ADULT, OLDER_ADULT
Phases:
Enrollment: 18000
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2015-06-30
Completion Date: 2015-06-30
Results First Posted:
Last Update Posted: 2017-03-29
Locations: Pharmatelligence, Cardiff, CF14 3QZ, United Kingdom
URL: https://clinicaltrials.gov/show/NCT02987348